Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin,warfarin,and the direct oral anticoagulants

Abstract

Background

Direct oral anticoagulants (DOACs) are not recommended for venous thromboembolism (VTE) treatment in patients with cancer because their safety and efficacy have not been compared to low molecular weight heparin (LMWH) in large trials. Routine anti-Xa monitoring in cancer patients on LMWH is also not recommended due to limited data correlating anti-Xa levels and outcomes.

Objective

Compare the safety and efficacy of DOACs to LMWH and warfarin and assess the relationship of anti-Xa monitoring and outcomes in patients with cancer taking LMWH in an urban university setting.

Methods

This retrospective, cohort study analyzed the recurrence of VTE and number of bleeding events in patients with cancer.

Results

There were 131 patients included in the analysis. There was no difference seen in the rate of recurrent VTEs between the LMWH, warfarin and DOAC groups (9.3%, 5.9%, 9.1%, p = 0.89). There was also no difference in the rate of bleeding between groups (10.5%, 14.7%, 9.1%, p = 0.576). There was an increased rate of mortality seen in the LMWH group (26.7% vs. 2.9% vs. 18.2%, p = 0.006). There was no difference seen in recurrent VTE (10.3% vs. 8.5%, p = 0.53) or bleeding (10.3% vs. 10.7%, p = 0.661) between the monitored and unmonitored LMWH patients.

Conclusion

Results of this analysis suggest DOACs may be as safe and effective as LMWH and warfarin for the treatment of VTE in patients with cancer, and there may be no clinical benefit to routine anti-Xa monitoring in patients on LMWH treatment. However, larger studies are needed to confirm these observations.

Keywords

Cancer low molecular weight heparins direct oral anticoagulants warfarin anti-Xa monitoring

Get full access to this article

View all access options for this article.

References

Cancer Prevalence: How Many People have cancer? http://www.cancer.org/cancer/cancerbasics/cancer-prevalence (accessed 26 August 2014).

Lee

Levine

. Venous thromboembolism and cancer: Risks and outcomes. Circulation 2003; 107: I–17.

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Cancer Associated Venous Thromboembolic Disease. Version 1. 2016.

Lyman

Bohlke

Korana

et al.

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol 2015; 33: 654–656.

Kearon

Ornelas

Blaivas

et al.

Antithrombotic therapy for VTE disease. Chest 2016; 149: 315–3521.

Garcia

Baglin

Weitz

et al.

Parenteral anticoagulants. Chest 2012; 141: e24S–e43S.

Vedovati

Germini

Agnelli

et al.

Direct oral anticoagulants in patients with VTE and cancer: A systematic review and meta-analysis. Chest 2015; 147: 475–483.

Posch

Königsbrügge

Zielinski

et al.

Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015; 136: 582–589.

Brunetti ND, Gesuete E, De Gennaro L, et al. Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: A meta-analysis study. Int J Cardiol 2016. DOI: http://dx.doi.org/10.1016/j.ijcard.2016.12.168.

10.

Schulman

Kearon

. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost 2005; 3: 692–694.

11.

Lee

Levine

Baker

et al.

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153.

12.

Lee

Kamphuisen

Meyer

et al.

A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients-the CATCH study. Blood 2014; 124: LBA–2.

13.

Büller

Prins

Lensin

et al.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–1297.

14.

Schulman

Kearon

Kakkar

et al.

Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–2352.

15.

Agnelli

Buller

Cohen

et al.

Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799–808.

16.

Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 2013: 1406–1415.

17.

Khorana

Carrier

Garcia

et al.

Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis 2016; 41: 81–91.

18.

Ross

Miller

Hernandez

. OC-13-Safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism. Thromb Res 2016; 140: S173–174.

19.

Pignataro BS, Nishinari K, Cavalcante RN, et al. Oral rivaroxaban for the treatment of symptomatic venous thromboembolism in 400 patients with active cancer. Clin Appl Thromb Hemost 2016.

20.

Mantha

Laube

Miao

et al.

Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: A prospective cohort study. J Thromb Thrombolysis 2016; 43: 166–171.

21.

Ross

Miller

Hernandez

. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis. Thromb Res 2017; 150: 86–89.

22.

Di Minno

Lupoli

Di Minno

et al.

Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: A meta-analysis of randomized controlled trials. Ann Med 2015; 47: 61–68.

23.

Martin

Beyer-Westendorf

Davidson

et al.

Use of the direct oral anticoagulants in obese patients: Guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14: 1308–1313.

24.

Smythe

Priziola

Dobesh

et al.

Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis 2016; 41: 165–186.

25.

Academic and Community Cancer Research United. Apixaban or Dalteparin in reducing blood clots in patients with cancer related venous thromboembolism. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. https://clinicaltrials.gov/ct2/show/NCT02585713 NLM Identifier: NCT02585713 (accessed 27 October 2016).

26.

AIO-Studien-gGmbH. Rivaroxaban in the treatment of venous thromboembolism (VTE) in cancer patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. https://clinicaltrials.gov/ct2/show/NCT02583191 NLM Identifier: NCT02583191 (accessed 27 October 2016).

27.

Alliance Foundation Trials, LLC. Direct oral anticoagulants (DOACs) versus LMWH +/− warfarin for VTE in cancer (CANVAS). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. https://clinicaltrials.gov/ct2/show/NCT02744092 NLM Identifier: NCT02744092 (accessed 27 October 2016).